-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 C+8s/N1y1515au1720GhUuao4aKEkkRSOn0bADnf8JIsKbopmndcp5Dax079VrPL
 MxNXZHTOQ/yAcy6BU2KGJA==

<SEC-DOCUMENT>0001362310-09-004998.txt : 20090408
<SEC-HEADER>0001362310-09-004998.hdr.sgml : 20090408
<ACCEPTANCE-DATETIME>20090407202100
ACCESSION NUMBER:		0001362310-09-004998
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090407
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090408
DATE AS OF CHANGE:		20090407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		09738659

	BUSINESS ADDRESS:	
		STREET 1:		6400 SOUTH FIDDLER
		STREET 2:		SUITE 1750
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80111
		BUSINESS PHONE:		720-488-1711

	MAIL ADDRESS:	
		STREET 1:		6400 SOUTH FIDDLER
		STREET 2:		SUITE 1750
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c83710e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): April 7, 2009 (April 6, 2009)</B>


<P style="font-size: 24pt" align="center"><B>Lifevantage
Corporation<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Colorado</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-30489</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>90-0224471</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>11545 W. Bernardo Court,
Suite 301, San Diego, California <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>92127</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(858) 312-8000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;3.02 Unregistered Sales
of Equity Securities</B>

<P style="font-size: 10pt" align="justify">On April&nbsp;6, 2009, Lifevantage
Corporation (the &#8220;Company&#8221;) held the third and final closing of an
offering to accredited investors of shares of Common Stock and warrants to
purchase Common Stock (the &#8220;Offering&#8221;). The Company sold 4,460,000
shares of Common Stock of the Company at a purchase price of $0.20 per share
and issued warrants exercisable for shares of Common Stock of the Company in
the third closing of the Offering, for aggregate gross proceeds of $892,000 in
the third closing. The Company sold an aggregate of 17,500,000 shares of Common
Stock of the Company at a purchase price of $0.20 per share and issued warrants
exercisable for 17,500,000 shares of Common Stock of the Company in the
Offering, for aggregate gross proceeds of $3,500,000. The warrants sold in the
Offering have an exercise price of $0.50 per share and may be exercised at any
time following issuance during the three year exercise period.

<P style="font-size: 10pt" align="justify">The Company issued a warrant to
purchase 1,500,000 shares of Common Stock of the Company to Aspenwood Capital
as part of the consideration for services provided to the Company by Aspenwood
Capital in connection with the Offering. The warrant issued to Aspenwood
Capital is identical to the form of warrant issued by the Company in the
Offering.

<P style="font-size: 10pt" align="justify">The shares and warrants were offered
and sold in the Offering only to persons who meet the definition of
&#8220;accredited investor&#8221; set forth in Rule 501(a) of Regulation&nbsp;D
promulgated under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), or to persons who are not &#8220;U.S. persons&#8221; as defined in
Regulation&nbsp;S under the Securities Act, pursuant to exemptions from
registration provided by Rule&nbsp;506 of Regulation&nbsp;D of the Securities
Act and Regulation&nbsp;S of the Securities Act.

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;7.01 Regulation&nbsp;FD
Disclosure</B>

<P style="font-size: 10pt" align="justify">On April&nbsp;7, 2009, the Company
issued a press release entitled, &#8220;Aspenwood Capital Raises $3.5 Million
for LifeVantage Corporation&#8221;. The press release is attached as
Exhibit&nbsp;99.1 hereto, which is furnished under Item&nbsp;7.01 of this
report and shall not be deemed to be &#8220;filed&#8221; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange
Act&#8221;) or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the Securities Act
or the Exchange Act, regardless of any general incorporation language in such
filing.

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;9.01 Exhibits</B>

<P style="font-size: 10pt; text-indent: 4%" align="justify">99.1 Press release,
dated April&nbsp;7, 2009, entitled, &#8220;Aspenwood Capital Raises $3.5
Million for LifeVantage Corporation&#8221;.

<P style="font-size: 10pt; text-indent: 4%" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt" align="justify">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.

<P style="font-size: 10pt" align="justify">Date: April&nbsp;7, 2009

<P style="font-size: 10pt; margin-left: 45%" align="justify">LIFEVANTAGE
CORPORATION

<P style="font-size: 10pt; margin-left: 45%" align="justify">By:
<U>/s/ Bradford K. Amman&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Bradford K. Amman<BR>
Chief Financial
Officer<BR>


<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap align="left"><B>Exhibit
No.</b></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><b>Description</b></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated April&nbsp;7, 2009,
entitled, &#8220;Aspenwood Capital Raises $3.5 Million for LifeVantage
Corporation&#8221;.</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c83710exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><B>FOR IMMEDIATE RELEASE</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>NEWS</B></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">April&nbsp;07, 2009<BR>
OTCBB: LFVN

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Contact:<BR>
LifeVantage</B><BR>
Patrick Courtemanche<BR>
612-746-1776<BR>
pat_court@yahoo.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Aspenwood Capital</B><BR>
Steve J. Ossello<BR>
720-533-4888, ext 1<BR>
sossello@aspenwoodcapital.com

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Aspenwood Capital Raises $3.5 Million for LifeVantage Corporation</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">SAN DIEGO, CA, April&nbsp;07, 2009 &#151; <u><B>LifeVantage Corporation</B></u><B> (OTCBB: LFVN) </B>announced today that
<B>Aspenwood Capital</B> (<u>www.AspenwoodCapital.com</u>), a Denver-based investment bank, has completed a $3.5
million private placement for the Company to accredited investors. LifeVantage
(<u>www.LifeVantage.com</u>) is a science based, natural products company, dedicated to helping people
reach their health and wellness goals through science-based solutions to oxidative stress.
LifeVantage is the maker of <u><B>Protandim</B></u><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; a dietary supplement clinically shown to induce
the body&#146;s own antioxidant defenses, and is developing an entire product line for its network
marketing program.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Aspenwood Capital partner Steve Ossello said, &#147;As active investment bankers for LifeVantage over
the past several years, we have always been tremendous supporters of the company and its primary
product &#151; Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. This capital raising effort is particularly gratifying now that
the company&#146;s exciting new network marketing strategy should provide Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> with the
distribution it richly deserves.&#148;
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">LifeVantage CEO and President David Brown said, &#147;We are extremely pleased with the success of this
raise. This vote of confidence from investors is an excellent reflection on the direction of the
Company and the many exciting developments that have recently occurred. The proceeds from this
financing should allow the Company to accomplish several goals, including the expansion of our
infrastructure and marketing efforts for our network marketing program.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Aspenwood Capital</B><BR>
Aspenwood Capital (<u>www.AspenwoodCapital.com</u>) of Denver, Colo., a division of Colorado Financial
Services Corporation (member FINRA / SIPC), specializes in providing investment banking services to
small-cap public issuers and late-stage private companies.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><u><B>About Protandim</B></u><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP><BR>
Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is a groundbreaking, clinically proven supplement that provides a substantial
benefit to help with the challenge of healthy aging. This patented antioxidant therapy is more
powerful than conventional foods such as red wine, oranges, blueberries or other popular
antioxidant supplements. Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> works by increasing the body&#146;s natural antioxidant
protection at the cellular level, triggering cells to produce naturally occurring protective
antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">A peer-reviewed human study showed that after Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> was taken for 30 consecutive
days, the accumulation of lipid peroxidation products (a biochemical marker of aging) was decreased
by an average of 40%. The study also reported that this important marker of aging was decreased
after taking Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> to the level of a typical 20&nbsp;year old. Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is
currently the subject of over 20 scientific studies at leading universities and research
institutes. For more information, please visit <u><B>www.LifeVantage.com</B></u><B>.</B>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><U><B>About LifeVantage Corporation</B></U>
LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science based, natural products
company, dedicated to helping people reach their health and wellness goals
through science-based solutions to oxidative stress. Founded in 2003 and based in San Diego, CA,
LifeVantage develops nutraceutical products, including <u><B>Protandim</B></u><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP><B>, </B>that leverage the
company&#146;s expertise and that are intended to deliver significant health benefits to consumers. For
more information, visit www.LifeVantage.com.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The Company uses the words &#147;anticipate,&#148;
&#147;believe,&#148; &#147;could,&#148; &#147;should,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;plan,&#148;
&#147;target&#148; and similar terms and phrases, including references to assumptions, to identify
forward-looking statements. These forward-looking statements are based on the Company&#146;s current
expectations and beliefs concerning future events affecting the Company and involve known and
unknown risks and uncertainties that may cause the Company&#146;s actual results or outcomes to be
materially different from those anticipated and discussed herein. These risks and uncertainties
include, among others, the risk that government regulators and regulations could adversely affect
our business; future laws or regulations may hinder or prohibit the production or sale of our
existing product and any future products; unfavorable publicity could materially hurt our business;
and the Company&#146;s ability to protect our intellectual property rights and the value of our product.
These and other risk factors are discussed in greater detail in the Company&#146;s Annual Report on
Form&nbsp;10-KSB under the caption &#147;Risk Factors&#148;, and in other documents filed the Company from time to
time with the Securities and Exchange Commission. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this document. All forward-looking
statements are based on information currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these forward-looking statements to reflect
events or circumstances after the date of this document, except as required by law.</I>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>*These statements have not been evaluated by the Food and Drug Administration. This product is not
intended to diagnose, treat, cure or prevent any disease.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">###
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Note to Editors: Contact Patrick Courtemanche at 612-746-1776 or pat_court@yahoo.com for
interviews, photography, and other requests.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
